14.76

1.79% 0.26

After Hours: 14.85 0.09 +0.61%

Biodesix Inc (BDSX)

Overview News Price History Option Chain Financials Discussions Forecast

Biodesix Inc stock is traded at $14.76, with a volume of 26,532. It is up +1.79% in the last 24 hours and down -3.72% over the past month. Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Previous Close:

$14.50

Open:

$14.48

24h Volume:

26,532

Relative Volume:

0.02

Market Cap:

$145.51M

Revenue:

$88.50M

Net Income/Loss:

$-35.27M

P/E Ratio:

-4.479

EPS:

-3.2954

Net Cash Flow:

$-23.70M

1W Performance:

-2.57%

1M Performance:

-3.72%

6M Performance:

+92.44%

1Y Performance:

+21.76%

1-Day Range:

$14.44

$15.20

1-Week Range:

$13.41

$15.50

52-Week Range:

$3.436

$20.21

Biodesix Inc Stock (BDSX) Company Profile

Name

Biodesix Inc

Sector

Healthcare (1116)

Industry

Diagnostics & Research (52)

Phone

303-417-0500

Address

919 WEST DILLON ROAD, LOUISVILLE

Employee

334

Twitter

Next Earnings Date

2025-10-31

Latest SEC Filings

BDSX's Discussions on Twitter

Compare BDSX vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDSX Biodesix Inc	14.76	142.95M	88.50M	-35.27M	-23.70M	-3.2954
TMO Thermo Fisher Scientific Inc	494.54	182.60B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	190.79	134.18B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	564.66	44.63B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.54	32.21B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	299.89	29.21B	3.17B	642.63M	516.49M	10.77

Biodesix Inc Stock (BDSX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Upgrade	William Blair	Mkt Perform → Outperform
May-14-25	Downgrade	William Blair	Outperform → Mkt Perform
Sep-16-24	Initiated	Scotiabank	Sector Outperform
Jul-26-24	Initiated	Craig Hallum	Buy
May-13-24	Initiated	TD Cowen	Buy
May-03-24	Initiated	Lake Street	Buy
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-23-20	Initiated	BTIG Research	Buy
Nov-23-20	Initiated	Canaccord Genuity	Buy
Nov-23-20	Initiated	Morgan Stanley	Overweight
Nov-23-20	Initiated	William Blair	Outperform

View All

Biodesix Inc Stock (BDSX) Latest News

Apr 01, 2026

Allworth Financial LP Reduces Holdings in Biodesix, Inc. $BDSX - marketbeat.com

Apr 01, 2026

Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com

Apr 01, 2026

Mar 31, 2026

Wall Street analysts see an 86.45% upside in Biodesix (BDSX): Can the stock really move this high? - MSN

Mar 31, 2026

Mar 30, 2026

AI Stocks: Can Biodesix Inc expand into new marketsMarket Growth Review & Technical Entry and Exit Tips - baoquankhu1.vn

Mar 30, 2026

Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 19.4% in March - MarketBeat

Mar 30, 2026

Mar 28, 2026

Weekly Earnings: What is the dividend yield of Biodesix IncQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

Biodesix publishes lung nodule biomarker validation study By Investing.com - Investing.com Australia

Mar 21, 2026

Mar 20, 2026

Biodesix, Inc.Common Stock (NQ: BDSX - markets.chroniclejournal.com

Mar 20, 2026

Biodesix publishes lung nodule biomarker validation study on 1,100 patients - Investing.com

Mar 20, 2026

Biodesix publishes lung nodule biomarker validation study - Investing.com

Mar 20, 2026

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis - The Manila Times

Mar 20, 2026

Biodesix Publishes Largest Lung Nodule Biomarker Study, Validating Nodify CDT® Test for Lung Cancer Risk Assessment - Quiver Quantitative

Mar 20, 2026

Study of 1,100 patients backs blood test for earlier lung cancer diagnosis - Stock Titan

Mar 20, 2026

Mar 19, 2026

Is Biodesix (BDSX) Shares Performing Better Than Other Medical Stocks This Year? - Bitget

Mar 19, 2026

Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High? - Yahoo Finance

Mar 19, 2026

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 19, 2026

Is Biodesix (BDSX) Shares Surpassing Other Medical Stocks This Year? - bitget.com

Mar 19, 2026

Mar 18, 2026

Treasury Yields: Can Biodesix Inc navigate macro headwinds2026 Pullbacks & Comprehensive Market Scan Insights - baoquankhu1.vn

Mar 18, 2026